BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Huang J" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Guanidinylated cluster-modified chitosan for wet-strength paper | Gu J; Gu Z; Wu B; Xiao S; Zheng S; Chen N; Zhuang J; Liu H; Jia Z; Meng Y; Cui X; Huang L; | 40947212 ENCS |
| 2 | Early family socioeconomic status and asthma-related outcomes in school-aged children: Results from seven birth cohort studies | Yang-Huang J; McGrath JJ; Gauvin L; Nikiéma B; Spencer NJ; Awad YA; Clifford S; Markham W; Mensah F; Andersson White P; Ludvigsson J; Faresjö T; Duijts L; van Grieken A; Raat H; | 38849153 PERFORM |
| 3 | Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22 | McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM; Ryan S; Raphael S; van Faassen H; Zafer A; Zhu Q; Maclean S; Chattopadhyay A; Gurnani K; Gilbert R; Gadoury C; Iqbal U; Fatehi D; Jezierski A; Huang J; Pon RA; Sigrist M; Holt RA; Nelson BH; Atkins H; Kekre N; Yung E; Webb J; Nielsen JS; Weeratna RD; | 38596311 BIOLOGY |
| 4 | Reinforcement learning for automatic quadrilateral mesh generation: A soft actor-critic approach | Pan J; Huang J; Cheng G; Zeng Y; | 36375347 ENCS |
| 5 | Household income and maternal education in early childhood and risk of overweight and obesity in late childhood: Findings from seven birth cohort studies in six high-income countries | White PA; Awad YA; Gauvin L; Spencer NJ; McGrath JJ; Clifford SA; Nikiema B; Yang-Huang J; Goldhaber-Fiebert JD; Markham W; Mensah FK; van Grieken A; Raat H; Jaddoe VWV; Ludvigsson J; Faresjö T; | 35821522 PERFORM |
| 6 | Maturation of temporal saccade prediction from childhood to adulthood: predictive saccades, reduced pupil size and blink synchronization | Calancie OG; Brien DC; Huang J; Coe BC; Booij L; Khalid-Khan S; Munoz DP; | 34759032 PSYCHOLOGY |
| 7 | Exploring the use of ceramic disk filter coated with Ag/ZnO nanocomposites as an innovative approach for removing Escherichia coli from household drinking water. | Huang J, Huang G, An C, Xin X, Chen X, Zhao Y, Feng R, Xiong W | 31864067 ENCS |
| 8 | Saccharification efficiencies of multi-enzyme complexes produced by aerobic fungi. | Badhan A, Huang J, Wang Y, Abbott DW, Di Falco M, Tsang A, McAllister T | 29803771 CSFG |
| 9 | New recombinant fibrolytic enzymes for improved in vitro ruminal fiber degradability of barley straw. | Ribeiro GO, Badhan A, Huang J, Beauchemin KA, Yang W, Wang Y, Tsang A, McAllister TA | 30053012 CSFG |
| 10 | Performance of ceramic disk filter coated with nano ZnO for removing Escherichia coli from water in small rural and remote communities of developing regions. | Huang J, Huang G, An C, He Y, Yao Y, Zhang P, Shen J | 29544196 ENCS |
| Title: | Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22 | ||||
| Authors: | McComb S, Arbabi-Ghahroudi M, Hay KA, Keller BA, Faulkes S, Rutherford M, Nguyen T, Shepherd A, Wu C, Marcil A, Aubry A, Hussack G, Pinto DM, Ryan S, Raphael S, van Faassen H, Zafer A, Zhu Q, Maclean S, Chattopadhyay A, Gurnani K, Gilbert R, Gadoury C, Iqbal U, Fatehi D, Jezierski A, Huang J, Pon RA, Sigrist M, Holt RA, Nelson BH, Atkins H, Kekre N, Yung E, Webb J, Nielsen JS, Weeratna RD | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/38596311/ | ||||
| DOI: | 10.1016/j.omton.2024.200775 | ||||
| Publication: | Molecular therapy. Oncology | ||||
| Keywords: | CAR optimization; CAR-T; CD22; MT: Regular Issue; cell therapy; chimeric antigen receptors; hematological malignancy; leukemia and lymphoma; nanobody; preclinical development; single-domain antibody; | ||||
| PMID: | 38596311 | Category: | Date Added: | 2024-04-10 | |
| Dept Affiliation: |
BIOLOGY
1 Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON, Canada. 2 Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 3 Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON, Canada. 4 Terry Fox Laboratory, British Columbia Cancer Research Institute, Vancouver, BC, Canada. 5 Division of Hematology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 6 Division of Anatomical Pathology, The Ottawa Hospital/University of Ottawa, Ottawa, ON, Canada. 7 University of Ottawa Faculty of Medicine, Ottawa, ON, Canada. 8 Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 9 Division of Hematopathology and Transfusion Medicine, The Ottawa Hospital/University of Ottawa, Ottawa, ON, Canada. 10 Department of Biology, Concordia University, Montréal, QC, Canada. 11 Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. 12 Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada. 13 Department of Molecular Biology & Biochemistry, Simon Fraser University, Burnaby, BC, Canada. 14 Deeley Research Centre, British Columbia Cancer Research Institute, Victoria, BC, Canada. 15 Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada. 16 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. |
||||
Description: |
Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to recombine than single-chain variable fragments (scFvs) used in most CARs, but fewer sdAb-CARs have been reported. Thus, we sought to identify a therapeutically active sdAb-CAR targeting human CD22. Immunization of an adult Llama glama with CD22 protein, sdAb-cDNA library construction, and phage panning yielded >20 sdAbs with diverse epitope and binding properties. Expressing CD22-sdAb-CAR in Jurkat cells drove varying CD22-specific reactivity not correlated with antibody affinity. Changing CD28- to CD8-transmembrane design increased CAR persistence and expression in vitro. CD22-sdAb-CAR candidates showed similar CD22-dependent CAR-T expansion in vitro, although only membrane-proximal epitope targeting CD22-sdAb-CARs activated direct cytolytic killing and extended survival in a lymphoma xenograft model. Based on enhanced survival in blinded xenograft studies, a lead CD22sdCAR-T was selected, achieving comparable complete responses to a benchmark short linker m971-scFv CAR-T in high-dose experiments. Finally, immunohistochemistry and flow cytometry confirm tissue and cellular-level specificity of the lead CD22-sdAb. This presents a complete report on preclinical development of a novel CD22sdCAR therapeutic. |
